Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

334 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Minoxidil in the treatment of androgenetic alopecia.
Goren A, Naccarato T. Goren A, et al. Dermatol Ther. 2018 Sep;31(5):e12686. doi: 10.1111/dth.12686. Epub 2018 Aug 28. Dermatol Ther. 2018. PMID: 30155952 Review.
In the US, minoxidil is approved over-the-counter (OTC) at a maximum concentration of 5%. In this review, we summarize the findings of the pivotal studies used in support of the drug's approval as well as recent discoveries and novel developments in the use of minoxidil fo …
In the US, minoxidil is approved over-the-counter (OTC) at a maximum concentration of 5%. In this review, we summarize the findings o …
Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics.
Keene S, Goren A. Keene S, et al. Among authors: goren a. Dermatol Ther. 2011 Mar-Apr;24(2):296-300. doi: 10.1111/j.1529-8019.2011.01407.x. Dermatol Ther. 2011. PMID: 21410621 Clinical Trial.
Variant repeat nucleotide sequences in exon 1 of the androgen receptor (AR) gene have been shown to determine androgen sensitivity in a variety of androgenic conditions in men and women. In an effort to identify whether this AR variant may help determine which women are li …
Variant repeat nucleotide sequences in exon 1 of the androgen receptor (AR) gene have been shown to determine androgen sensitivity in a
In vitro evaluation of a novel topical cream for vitiligo and psoriasis that selectively delivers NB-UVB therapy when exposed to sunlight.
McCoy J, Goren A, Lotti T. McCoy J, et al. Among authors: goren a. Dermatol Ther. 2014 Mar-Apr;27(2):117-20. doi: 10.1111/dth.12079. Epub 2013 Jul 16. Dermatol Ther. 2014. PMID: 23952638
While the treatment efficacy of NB-UVB artificial light sources is well documented, the long term time and cost commitment of the therapy remains a barrier to treatment adherence. ...This communication describes a novel topical cream designed to selectively deliver …
While the treatment efficacy of NB-UVB artificial light sources is well documented, the long term time and cost commitment of the therapy re …
Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia.
Goren A, Castano JA, McCoy J, Bermudez F, Lotti T. Goren A, et al. Dermatol Ther. 2014 May-Jun;27(3):171-3. doi: 10.1111/dth.12111. Epub 2013 Nov 27. Dermatol Ther. 2014. PMID: 24283387
To observe significant improvement in hair growth, minoxidil is typically used daily for a period of at least 3-4 months. Due to the significant time commitment and low response rate, a biomarker for predicting patient response prior to therapy would be advantageous …
To observe significant improvement in hair growth, minoxidil is typically used daily for a period of at least 3-4 months. Due to the …
Novel topical cream delivers safe and effective sunlight therapy for vitiligo by selectively filtering damaging ultraviolet radiation.
Goren A, Salafia A, McCoy J, Keene S, Lotti T. Goren A, et al. Dermatol Ther. 2014 Jul-Aug;27(4):195-7. doi: 10.1111/dth.12115. Epub 2014 Feb 18. Dermatol Ther. 2014. PMID: 24548413 Clinical Trial.
We conducted a pilot study at sea level to assess the efficacy of a novel topical cream that selectively filters nontherapeutic wavelengths of UVB from natural sunlight and delivers treatment for acrofacial vitiligo. ...Our results demonstrate that the novel topical …
We conducted a pilot study at sea level to assess the efficacy of a novel topical cream that selectively filters nontherapeuti …
Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia.
Roberts J, Desai N, McCoy J, Goren A. Roberts J, et al. Among authors: goren a. Dermatol Ther. 2014 Jul-Aug;27(4):252-4. doi: 10.1111/dth.12130. Epub 2014 Apr 28. Dermatol Ther. 2014. PMID: 24773771 Clinical Trial.
As such, a biomarker for predicting treatment response would have significant clinical utility. In a previous study, Goren et al. reported an association between sulfotransferase activity in plucked hair follicles and minoxidil response in a mixed coho …
As such, a biomarker for predicting treatment response would have significant clinical utility. In a previous study, Goren
Novel topical cream delivers safe and effective alternative to traditional psoriasis phototherapy.
Goren A, Salafia A, McCoy J, Keene S, Lotti T, Petrusevska A. Goren A, et al. Dermatol Ther. 2014 Sep-Oct;27(5):260-3. doi: 10.1111/dth.12132. Epub 2014 Apr 28. Dermatol Ther. 2014. PMID: 24773915 Clinical Trial.
In today's environment of shrinking reimbursement and coverage for many health care procedures, phototherapy for psoriasis has experienced a major decline. ...In particular, 43% of the treatment group experienced complete clearance and the remainder experienced at a
In today's environment of shrinking reimbursement and coverage for many health care procedures, phototherapy for psoriasis has experienced …
Acute telogen effluvium onset event is associated with the presence of female androgenetic alopecia: potential therapeutic implications.
Perez-Mora N, Goren A, Velasco C, Bermudez F. Perez-Mora N, et al. Among authors: goren a. Dermatol Ther. 2014 May-Jun;27(3):159-62. doi: 10.1111/dth.12101. Dermatol Ther. 2014. PMID: 24850277
Conclusions are as follows: (i) Triggering cause is a significant independent factor that predicts association of ATE with FAA. ...(iv) Minoxidil use shows a trend to lower the percentage of progression to CTE. (v) Apart from treating the precipitating cause, the di …
Conclusions are as follows: (i) Triggering cause is a significant independent factor that predicts association of ATE with FAA. ...(i …
Clinical utility and validity of minoxidil response testing in androgenetic alopecia.
Goren A, Shapiro J, Roberts J, McCoy J, Desai N, Zarrab Z, Pietrzak A, Lotti T. Goren A, et al. Dermatol Ther. 2015 Jan-Feb;28(1):13-6. doi: 10.1111/dth.12164. Epub 2014 Aug 12. Dermatol Ther. 2015. PMID: 25112173
Given the prolonged treatment time required to elicit a response, a diagnostic test for ruling out nonresponders would have significant clinical utility. Two studies have previously reported that sulfotransferase enzyme activity in plucked hair follicles predicts …
Given the prolonged treatment time required to elicit a response, a diagnostic test for ruling out nonresponders would have si …
Topical cream delivers NB-UVB from sunlight for the treatment of vitiligo.
Wang X, McCoy J, Lotti T, Goren A. Wang X, et al. Among authors: goren a. Expert Opin Pharmacother. 2014 Dec;15(18):2623-7. doi: 10.1517/14656566.2014.978287. Epub 2014 Nov 3. Expert Opin Pharmacother. 2014. PMID: 25363734
Here, we discuss how this novel topical cream could provide a convenient alternative to artificial light phototherapy....
Here, we discuss how this novel topical cream could provide a convenient alternative to artificial light phototherapy....
334 results
Jump to page
Feedback